CSPC Innovation (300765.SZ) subsidiary SYS6002 announces research findings at the 2026 International Gynecologic Cancer Society Global Annual Meeting

Zhitong Finance APP news, CSPC Innovation (300765.SZ) announced that its controlling subsidiary, CSPC Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jushi Biopharmaceutical"), presented the Phase I clinical study data of SYS6002 monotherapy for the treatment of advanced cervical cancer in a rapid oral presentation at the 2026 International Gynecologic Cancer Society Annual Global Meeting (IGCS Annual Global Meeting) held in Montreal, Canada, from October 1 to October 3.